The Chicago Entrepreneur

: Amid criticism for its handling of another Alzheimer’s drug, FDA will decide this week whether to approve lecanemab

A damning new congressional report found the regulator didn’t follow the correct procedures when it approved Aduhelm in 2021

Previous post The Ratings Game: China is now a ‘reopening’ story for Starbucks, analysts say. Here’s what to watch for next.
Next post McCarthy on track to lose in third round of voting as he tries to become House speaker